MSGERC |
ECMM |
|
Monica Slavin Peter G. Pappas Luis Ostrosky-Zeichner Dimitrios P. Kontoyiannis Jessica Little George R. Thompson, III Thomas F. Patterson Gerald McGwin |
Martin Hoenigl Bart Jan Rijnders Ritesh Agarwal Oliver A. Cornely Jean Pierre Gangneux Cornelia Lass-Florl Johan Martens Marcio Nucci |
(Pictured Above: Oliver Cornely, Jean Pierre Gangneux, GR Thompson, Connie Lass-Florl, Tom Patterson, Jessica Little,
Carolynn Jones, Monica Slavin, Johan Maertens, Bart Jan Rijnders, Martin Hoenigl, Ritesh Agarwal)
After initial organizing meetings by Zoom, the Aspergillus and Other Molds Subcommittee met in Milan, Italy on January 23 & 24, 2024 at the Rosa Grand Hotel (prior to the 11th Advances Against Aspergillus and Mucormycosis Conference in Milan).
During this meeting, the group aimed to redefine Clinical Mycology Response Criteria for clinical trials and treatment, ensuring MSGERC and ECMM collaborative consensus. The members of the group (pictured above) met in person, but also enabled segments of the meeting to inclue those workgroup members who were unable to attend in person, via Zoom conferencing.
The group reviewed the Segal, et al, 2008 response criteria and more current evidence surrounding: new trial designs, impact of current outcomes; DRC review criteria issues, real world evidence; emerging diagnostics, patient important outcomes and the published literature.
The resulting consensus document was presented at the ECMM/MSGERC Listening Session # 2 that included EMA, FDA, CDC. and other clinicians.
The group continued to have a series of Zoom conferences and email exchanges to finalize the product, including solicitation of pediatric feedback.
The draft guidelines were presented by Monica Slavin and Martin Hoenigl at the MSGERC Biennial Meeting, September 2024 in Colorado Springs, Colorado, USA, pending final edits from pediatric infectious disease consultants.
In October, 2024, the final revised Draft will be disseminated for public comment and will include feedback from patient representatives who are survivors of aspergillus/mould infections. An announcement to the membership of MSGERC and ECMM will also be disseminated for for public comment viewing of the document.
The final guidelines will be submitted for publication after a period of public comment and final revisions in Autumn, 2024.
(Under Construction)
Under Construction